



# GROUPE SEBBIN

## the future with a smile

In recent months, breast implants have been the focus of a debate that attracted intense media coverage. In a sneak preview to the Anti-Ageing Medicine World Congress in Monaco, Olivier Pérusseau, Director of the Sebbin Group, answered the questions of Anti-Age Magazine on this current topic, the position of Sebbin and its future.

**AAM: In a few words, how would you introduce the Laboratoires Sebbin?**

**O.P.:** Since 1986, the Sebbin Group creates, develops manufactures and markets high-quality silicone implants for aesthetic and reconstructive surgery. Our company, based near Paris, vouches for the reliability and high quality of its products. It is of higher priority today than ever before, through the strictest adherence to a code of ethics, that we wish to maintain the peace of mind of surgeons and patients who choose our implants.

**AAM: How do you guarantee the safety of your implants?**

**O.P.:** In addition to the mechanical and biocompatibility tests performed on the implants by independent laboratories to obtain CE certification of the products, any person working within the Sebbin Group is trained and thus realizes that the product manufactured and sold by the company will one day be implanted in a human body. The Laboratoires Sebbin only uses biocompatible medical grade primary materials, with long term implantability, that are registered with the FDA (Food & Drugs Administration). 100% of implants are examined singly, by hand, at key stages in their manufacture in order to assure the best quality for the patients. There is a true bond of trust between the surgeons and their patients, a relationship of trust that we form a part of.

**AAM: How is the Sebbin Group positioned at the international level?**


**O.P.:** We export our implants principally to Europe and South America and we are developing in Northern Africa, Asia and the Middle East. The Sebbin Group is present in over 50 countries with high-growth international sales.

**AAM: How do you envisage the future of the Sebbin Group?**

**O.P.:** Where breast implants constitute a significant part of our activity, with a complete range of products comprising textured and smooth but also inflatable round implants, anatomical implants, we are also present, not without a certain level of success, on the "niche" markets and innovative markets.

**AAM: What kind?**

**O.P.:** Technical products make it possible to meet the specific needs of our partner surgeons: testicular implants calf implants, gluteal implants, skin expanders of various shapes but also facial implants. Always with the same code of ethics of respect for patients and mastered manufacturing processes.



© Reuters

**AAM: Are you thinking of continuing to develop innovative solutions?**

**O.P.:** The future of aesthetic and reconstructive surgery is strongly linked to inventiveness, as much from the practitioners as from the laboratories. It is from this perspective that we benefit from a close relationship with our partners and that we assign an ever growing part to our efforts in research and development. For example, as of 2010, we developed an innovative technique for producing custom-made implants, particularly designed to correct congenital deformities or those caused by trauma generally located at the thorax (funnel chest for example). In collaboration with specialized partners, this technique is based on 3D computer-aided design technology which facilitates the design of a custom-made implant from an imprint or from a scanned image of the area in the patient requiring correction.

**AAM: What were the strong periods of 2011?**

**O.P.:** This 3D technology for custom-made implants has allowed the Laboratoires Sebbin to be awarded the innovation prize by PM'UP Ile de France and OSEO.

And recently, Sebbin is operating in the field of facial rejuvenation, especially with the technique of lipofilling and the more innovative method of "microfilling". We provide practitioners with kits for treatment of adipose tissue comprising single-use cannulas. Compared to standard methods and due to the narrow diameter of the cannulas both for lipoaspiration and reinjection, microfilling allows augmentation or filling of volume, with the advantage of using a less sizeable quantity of fatty tissue that is of superior quality. This technique allows an optimal result to be obtained, painlessly and without trauma, with recovery taking less than 48 hours. At the end of 2011, the innovation prize was awarded to the Sebbin Group for this product during the 56th Congress of the French Society of Plastic, Reconstructive and Aesthetic surgery (SOFCPRE).

**AAM: Olivier Pérusseau - thank you**